Johnson & Johnson (JNJ.F)
| Previous Close | 136.32 |
| Open | 136.10 |
| Bid | 136.14 x 30000 |
| Ask | 136.48 x 30000 |
| Day's Range | 136.10 - 136.80 |
| 52 Week Range | 132.74 - 160.40 |
| Volume | |
| Avg. Volume | 1,053 |
| Market Cap | 329.234B |
| Beta (5Y Monthly) | 0.53 |
| PE Ratio (TTM) | 21.78 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 4.55 (3.32%) |
| Ex-Dividend Date | May 20, 2024 |
| 1y Target Est | N/A |
- PR Newswire
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
Johnson & Johnson (NYSE: JNJ) today announced positive results from the nipocalimab Phase 3 Vivacity-MG3 study in patients with generalized myasthenia gravis (gMG). Patients treated with nipocalimab plus standard of care (SOC) achieved superiority over placebo plus SOC as measured by the primary endpoint of improvement in the MG-ADL score from baseline over 24 weeks. These data are included in a presentation and are among eight abstracts that Johnson & Johnson will present at the European Academ
- Business Wire
Johnson & Johnson Completes Acquisition of Proteologix, Inc.
NEW BRUNSWICK, N.J., June 21, 2024--Johnson & Johnson (NYSE: JNJ) announced today that it has successfully completed the acquisition of Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash with potential for an additional milestone payment, as announced on May 16, 2024.
- PR Newswire
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease
Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active Crohn's disease. This marks the second submission to the FDA for TREMFYA® in inflammatory bowel disease this year following an application in March for moderately to severely active ulcerative colitis.a
